RemeGen’s telitacicept delivered a statistically significant reduction in proteinuria in a prespecified interim analysis of a Phase 3 trial in biopsy-proven IgA nephropathy. In patients at high risk for progression, 39 weeks of once-weekly subcutaneous telitacicept reduced the 24-hour urinary protein-to-creatinine ratio by 58.9% versus 8.8% with placebo.